The easiest-to-use single-dose COVID-19 vaccine is close to spreading out, promising theoretically to significantly boost the U.S. frantic vaccination campaign. But J & J’s early stocks are very limited, a White House adviser said Wednesday.
Following the FDA’s forthcoming emergency approval of the vaccine in early March, the company will have just “a few million doses” ready to go, President Joe Biden’s coronavirus response coordinator Jeffrey Zients said: at a press conference, as reported by the New York Times.
J & J ‘s contract with the federal government, which entered into last summer, requires the drug dealer to deliver 100 million doses by the end of June. But it now looks like delivery will be “loaded at the back end,” Zients said.
Anthony Fauci, the White House’s chief medical adviser, said the government expected “much more” doses immediately, as CNBC reported. He said it was “somewhat disappointing that the number of doses we are going to make early is very small,” but that the numbers will go up in the spring.
The government has been aware for weeks of what J&J expected for limited initial supply. Janssen representatives previously said “about 2 million doses will be delivered at the time of an emergency use permit,” according to a GAO report released last month. Zients said this week that officials are “doing what we can to speed up the delivery schedule. ”
LOVE: Johnson & Johnson ‘comfortable’ meets coronavirus vaccine delivery promises, CFO says
Johnson & Johnson’s single-dose vaccine is stable at cooling temperatures, offering a diffusion edge over authorized mRNA images from Pfizer and Moderna. The J&J program is set for an FDA hearing to review data next week.
During an employment call with analysts last month, J&J execs did not mention any problems that could disrupt its delivery plans. CFO Joe Wolk said the drug dealer was “very comfortable” meeting J & J ‘s dose promises in the U.S. and elsewhere, but that “there is still some fluency in timelines. ”
J&J would not address Zients’ statements specifically Thursday. The company “expects to deliver 100 million doses to the U.S. in the first half of 2021,” a spokesman said, and they “expect a product to be available immediately upon approval.”
LOVE: While Pfizer and Moderna take the lead, new data from J&J, Novavax shows there is ‘a place for everyone’ in the market: analysts
In phase 3 results released last month, the J&J vaccine was 72% effective in the U.S. and 66% effective overall in preventing moderate- COVID-19 inhibition. heavily. The vaccine also provided “complete protection” against COVID-related hospitalization and day 28 death.
The U.S. release would push for the picture the country’s vaccination effort at a crucial time. Things have been falling from a high in January, but experts are urging swift vaccines to get ahead of changes that could prevent the vaccine. Biden said this week that Americans seeking vaccination should be able to get one by the end of July.